CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.7 CNY | +0.85% |
|
-0.57% | -12.67% |
| Sales 2024 * | 1.43B 197M | Sales 2025 * | 1.76B 243M | Capitalization | 6.63B 915M |
|---|---|---|---|---|---|
| Net income 2024 * | 284M 39.19M | Net income 2025 * | 358M 49.4M | EV / Sales 2024 * | 4.65 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.77 x |
| P/E ratio 2024 * |
23.6
x | P/E ratio 2025 * |
18.7
x | Employees | 1,400 |
| Yield 2024 * |
1.36% | Yield 2025 * |
1.63% | Free-Float | 45.41% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.85% | ||
| 1 week | -0.57% | ||
| Current month | -0.57% | ||
| 1 month | -6.72% | ||
| 3 months | +9.93% | ||
| 6 months | -2.81% | ||
| Current year | -12.67% |
1 week
54.25
57.47
1 month
54.2562.40
Current year
43.4163.87
1 year
43.4164.25
3 years
43.4165.88
5 years
41.8588.00
10 years
41.8588.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Xu Yuan
CEO | Chief Executive Officer | 53 | 08-12-31 |
Ying Wang
FOU | Founder | 58 | 09-05-31 |
Jia Yu Zhu
CHM | Chairman | 44 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Wu Geng
BRD | Director/Board Member | 56 | 21-12-22 |
Ying Wang
FOU | Founder | 58 | 09-05-31 |
Da Ming Zhang
BRD | Director/Board Member | 52 | 08-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 55.7 | +0.85% | 234,156 |
| 24-06-06 | 55.23 | +0.24% | 461,280 |
| 24-06-05 | 55.1 | -0.31% | 263,424 |
| 24-06-04 | 55.27 | -0.05% | 481,830 |
| 24-06-03 | 55.3 | -1.29% | 648,163 |
End-of-day quote Shanghai S.E., June 06, 2024
More quotes
Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The Company operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
55.7
CNY
Average target price
75
CNY
Spread / Average Target
+34.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.67% | 907M | |
| +45.82% | 754B | |
| +40.95% | 630B | |
| -6.16% | 352B | |
| +19.86% | 331B | |
| +9.32% | 298B | |
| +18.45% | 250B | |
| +11.88% | 217B | |
| -0.78% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- 688513 Stock
